Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09GJI
|
||||
| Former ID |
DNC008630
|
||||
| Drug Name |
7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [529625] | ||
| Formula |
C18H16N2O
|
||||
| Canonical SMILES |
CC(C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)O)N4C=CN=C4
|
||||
| InChI |
1S/C18H16N2O/c1-12(20-7-6-19-11-20)13-2-4-17-14(8-13)9-15-10-16(21)3-5-18(15)17/h2-8,10-12,21H,9H2,1H3
|
||||
| InChIKey |
LVWQDZJSHTWZHR-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 11B1, mitochondrial | Target Info | Inhibitor | [529625] | |
| 17 alpha-hydroxylase-C17, 20-lyase | Target Info | Inhibitor | [529625] | ||
| PathWhiz Pathway | SteroidogenesisPW000045:Androgen and Estrogen Metabolism | ||||
| Steroidogenesis | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Oxidation by Cytochrome P450 | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| Corticotropin-releasing hormoneWP702:Metapathway biotransformation | |||||
| Steroid Biosynthesis | |||||
| Glucocorticoid & Mineralcorticoid Metabolism | |||||
| Prostate Cancer | |||||
| Phase 1 - Functionalization of compounds | |||||
| References | |||||
| Ref 529625 | Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. Epub 2008 Jul 9.Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge. | ||||
| Ref 529625 | Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. Epub 2008 Jul 9.Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge. | ||||